

28 April, 2021

Deltex Medical Group plc
(“Deltex Medical” or the “Group”)

Grant of options

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), announces that yesterday, 27 April 2021, the Board approved the issue of 14.5 million share options to 7 existing employees and to Andy Mears, Chief Executive Officer, under the Company’s 2003 Share Option Scheme (the “**EMI Share Scheme**”).

Employee Share Option Scheme

Incorporated into the EMI Share Scheme, the Board has approved the issue of 5,000,000 share options to Andy Mears, Chief Executive. The exercise price for these shares is 1.80 pence per share option, the closing price on 27 April 2021. The share options for the Chief Executive may ordinarily be exercised between April 2024 and April 2031 and are subject to performance conditions which are based on achieving certain specified earnings targets.

On 22 July 2020 the Company announced that it had granted 4,000,000 share options to Andy Mears, Chief Executive Officer, and 1,000,000 to David Moorhouse, Group Finance Director. This should have said that the options were awarded under the 2011 Executive Share Scheme rather than the 2003 EMI Share Scheme.

Confirmation of Directors’ interests in share options

Following the grant of EMI options above, the options held by Directors are shown below:

Executive Director	2011 Executive Share Scheme Number	2003 EMI Share Scheme Number	Total Number
Andy Mears	6,387,500	15,000,000	21,387,500
David Moorhouse	1,000,000	-	1,000,000

Nigel Keen, Deltex Medical’s Chairman, commented:

“The Company has navigated its way through the lockdown period successfully. All the indications are present that elective surgery will return to more normal levels in the second half of 2021. The Company is well placed to take advantage of this and the Board wished to motivate key employees by awarding these share options.”

For further information, please contact:

Deltex Medical Group plc
Nigel Keen, Chairman
Andy Mears, Chief Executive
David Moorhouse, Group Finance Director

01243 774 837
investorinfo@Deltexmedical.com

Arden Partners plc
Paul Shackleton
Dan Gee-Summons

020 7614 5900

Joint Broker
Turner Pope Investments (TPI) Ltd

0203 657 0050

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	a. Andy Mears (Chief Executive) b. David Moorhouse (Group Finance Director)
2	Reason for the notification	
a)	Position/status	See 1 a) above
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Deltex Medical Group plc
b)	LEI	213800XN34P6L18J6M39
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Issue of share options Identification code (ISIN) for Deltex Medical Group plc ordinary shares: GB0059337583
b)	Nature of the transaction	Issue of options
c)	Price(s) and volume(s)	Issue of share options a. 5,000,000
d)	Aggregated information - Aggregated volume - Price	5,000,000 Exercisable at 1.80 pence
e)	Date of the transaction	27.4.21
f)	Place of the transaction	Outside a trading venue

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily used in critical care and general surgical procedures. Deltex Medical's proprietary oesophageal Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic space to have built a robust and credible evidence base demonstrating both the clinical and economic benefits of its core technology: TrueVue Doppler. This technology has been proven in a wide range of clinical trials to reduce complications suffered by patients after surgery and consequently can save hospitals money.

Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which transmits low magnitude, high frequency electrical signals through the thorax and measures the changes to this signal when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

Group goal

Haemodynamic management is now becoming widely accepted as a vital part of the anaesthesia protocols for surgical patients, as well as treating ventilated intensive care patients, including ventilated COVID-19 patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's clinical condition as well as the skill and expertise of the user. Doing this will enable the Group to partner with healthcare providers to support modern haemodynamic management across the whole hospital.

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA, and via agreements with approximately 40 distributors overseas.